Biochemical Aspects, Laboratory Diagnosis and Follow-Up of High Blood Cholesterol: NCEP ATP III Guidelines

Open access

Biohemijski Aspekti, Laboratorijska Dijagnoza I Praćenje Povišene Koncentracije Holesterola: Preporuke NCEP ATP III

Treći izveštaj ekspertske grupe o detekciji, evaluaciji i tretmanu povišene koncentracije holesterola u odraslih (Adult Treatment Panel III, ATP III) predstavlja ažuriran klinički vodič Nacionalnog programa edukacije o holesterolu (National Cholesterol Education Program, NCEP), o određivanju holesterola i zbrinjavanju osoba s povišenom koncentracijom holesterola u serumu. Pored toga što preporučuje intenzivan tretman pacijenata sa koronarnom srčanom bolešću (coronary heart disease/CHD), važna karakteristika ATP III je težište na primarnoj prevenciji kod osoba sa više prisutnih faktora rizika. ATP III nastavlja da identifikuje povišene koncentracije LDL holesterola kao primarni cilj terapije za snižavanje holesterola. Osnovni princip prevencije je da se intenzitet terapije prilagođava apsolutnom riziku za CHD svake osobe pojedinačno. Procena rizika podrazumeva određivanje LDL holesterola u sklopu analize lipoproteina i identifikaciju pratećih determinanti rizika (prisustvo ili odsustvo CHD, drugih kliničkih oblika aterosklerotske bolesti i dijabetesa, pušenje, hipertenzija, niska koncentracija HDL holesterola, porodična anamneza prevremene pojave CHD, starost). U kategoriji najvišeg rizika nalaze se osobe sa CHD i CHD ekvivalentima rizika, čiji je apsolutni rizik od pojave srčane smrti ili nefatalnog infarkta miokarda u narednih 10 godina ≥20%. Drugu kategoriju čine osobe sa dva ili više faktora rizika kod kojih je 10-godišnji rizik <20%. Apsolutni rizik se procenjuje na osnovu Framingham rizik skora. U trećoj kategoriji su osobe sa jednim ili nijednim faktorom rizika. Definisane su preporučene koncentracije LDL holesterola za svaku kategoriju i postižu se korekcijom ishrane i/ili farmakoterapijom. Evropske preporuke za prevenciju kardiovaskularne bolesti (cardiovascular disease, CVD) u kliničkoj praksi preporučuju upotrebu SCO-RE (Systematic COronary Risk Evaluation) tablica za procenu rizika za pojavu CVD, koje podrazumevaju apsolutnu verovatnoću za fatalan ishod CVD u toku 10 godina. Cilj ovog rada je predstavljanje delova NCEP ATP III i evropskih preporuka značajnih za njihovu implementaciju u laboratorijsku praksu.

Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106: 3143-421.

Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.

Wilson PW F, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.

Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-8.

Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I: Reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351-64.

Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74.

Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367-72.

Law MR. Lowering heart disease risk with cholesterol reduction: evidence from observational studies and clinical trials. Eur Heart J Suppl 1999; Suppl S: 3-8.

Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and metaanalysis. BMJ. 2003; 326: 1423.

Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92: 1355-74.

Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet 1999; 353: Suppl II: 5-9.

Brown BG, Stewart BF, Zhao X-Q, Hillger LA, Poulin D, Albers JJ. What benefit can be derived from treating normocholesterolemic patients with coronary artery disease? Am J Cardiol 1995; 76: 93C-7C.

Grundy SM. Cholesterol-lowering trials: a historical perspective. In: Grundy SM, editor. Cholesterol lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc., 2000: 1-329.

Austin MA, Hokanson JE, Edwards KL. Hypertrigly-ceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B-12B.

Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998; 81: 13B-7B.

Breslow JL. Mouse models of atherosclerosis. Science 1996; 272: 685-8.

Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J, et al. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis 1996; 122: 105-15.

Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 2001; 42: 17-21.

Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102: 1886-92.

Havel RJ. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol 2000; 11: 615-20.

Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994; 78: 117-41.

Levinson SS, Wagner SG. Measurement of apolipoprotein B-containing lipoproteins for routine clinical laboratory use in cardiovascular disease. Arch Pathol Lab Med 1992; 116: 1350-4.

Kwiterovich PO Jr Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol 1992; 69: 1015-21.

Gotto AM Jr Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101: 477-84.

Vega GL, Grundy SM. Does measurement of apolipoprotein B have a place in cholesterol management [Editorial]? Arteriosclerosis 1990; 10: 668-71.

Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation 1979; 60: 427-39.

Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79: 8-15.

Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998; 19: Suppl A: 31-5.

van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758-67.

Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein. J Lipid Res 2000; 41: 1481-508.

Vega GL, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol 1996; 7: 209-16.

Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994; 35: 871-82.

Rainwater DL. Lipoprotein correlates of LDL particle size. Atherosclerosis 2000; 148: 151-8.

Martin-Jadraque R, Tato F, Mostaza JM, Vega GL, Grundy SM. Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels. Arch Intern Med 1996; 156: 1081-8.

Kastelein JJ P, Isaacsohn JL, Ose L, Hunninghake DB, Frohlich J, Davidson MH, et al. for the Simvastatin Atorvastatin HDL Study Group. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol 2000; 86: 221-3.

Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506.

National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obesity Res 1998; 6: Suppl 2: 51-209.

Miettinen H, Lehto S, Salomaa V, Mähönen M, Niemelä M, Haffner SM, et al., for the FINMONICA Myocardial Infarction Register Study group. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998; 21: 69-75.

Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3: 463-524.

Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999; 83: 25F-9F.

Meigs JB. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000; 152: 908-11.

Zimmet P, Boyko EJ, Collier GR, de Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann NY Acad Sci 1999; 892: 25-44.

Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM): results of follow-up at 8 years. Eur Heart J 1998; 19: Suppl A: 2-11.

Eckel RH, Krauss RM., for the AHA Nutrition Committee. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. Circulation 1998; 97: 2099-100.

Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab 1999; 1: Suppl 1: 1-7.

Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000; 106: 329-33.

Dengel DR, Galecki AT, Hagberg JM, Pratley RE. The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older men. Am J Hypertens 1998; 11: 1405-12.

Devlin JT. Effects of exercise on insulin sensitivity in humans. Diabetes Care 1992; 15: 1690-3.

JNC VI. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.

Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96: 2751-3.

Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.

Peduzzi P, Kamina A, Detre K., for the VA Coronary Artery Bypass Surgery Cooperative Study Group. Twenty-two-year follow-up in the VA Cooperative Study of Coronary Artery Bypass Surgery for Stable Angina. Am J Cardiol 1998; 81: 1393-9.

Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, et al., for the MARS Research Group. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993; 119: 969-76.

Brown BG, Bardsley J, Poulin D, Hillger LA, Dowdy A, Maher VM G, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce lowdensity lipoprotein cholesterol <100 mg/dL in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 1997; 80: 111-5.

Kroon AA, Aengevaeren WR M, van der WT, Uijen GJ H, Reiber JH C, Bruschke AV G, et al. LDLApheresis Atherosclerosis Regression Study (LAARS): effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996; 93: 1826-35.

Leng GC, Fowkes FG R, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 1996; 313: 1440-3.

McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991; 87: 119-28.

Ferguson GC, Eliasziw M, Barr HW K, Clagett GP, Barnes RW, Wallace C, et al., for the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Collaborators. The North American Symptomatic Carotid Endarterectomy Trial: surgical results in 1415 patients. Stroke 1999; 30: 1751-8.

Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997; 146: 483-94.

Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu C, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262-9.

Hertzer NR. Fatal myocardial infarction following abdominal aortic aneurysm resection: three hundred forty-three patients followed 6-11 years postoperatively. Ann Surg 1980; 192: 667-73.

Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al, for the OASIS Registry Investigators. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000; 102: 1014-9.

Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.

National Cholesterol Education Program. Risk assessment tool for estimating 10-year risk of developing hard CHD (myocardial infarction and coronary death). http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7-22.

Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al., for PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. PROspective Study of Pravastatin in the Elderly at Risk. Lancet 2002; 360: 1623-30.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL-HAT-LLT). JAMA 2002; 288: 2998-3007.

Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al., ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.

Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.

Grundy SM, Cleeman JI, Bairey Merz CN, Brewer B Jr Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatmant Panel III guidelines. Circulation 2004; 110: 227-39.

Hunninghake DB. Drug treatment of dyslipoproteinemia. Endocrinol Metab Clin North Am 1990; 19: 345-60.

Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-5.

Tatò F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum lowdensity lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol 1998; 81: 805-7.

Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264: 723-6.

Gore JM, Goldberg RJ, Matsumoto AS, Castelli WP, McNamara PM, Dalen JE. Validity of serum total cholesterol level obtained within 24 h of acute myocardial infarction. Am J Cardiol 1984; 54: 722-5.

Bachorik PS, Ross JW, for the National Cholesterol Education Program Working Group on Lipoprotein Measurement. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. Clin Chem 1995; 41: 1414-20.

Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein A1 and apolipoprotein B plasma levels. J Int Med 2006; 259: 437-46.

Stein EA, Myers GL., for the National Cholesterol Education Program Working Group on Lipoprotein Measurement. National Cholesterol Education Program recommendations for triglyceride measurement: executive summary. Clin Chem 1995; 41: 1421-6.

Warnick GR, Wood PD., for the National Cholesterol Education Program Working Group on Lipoprotein Measurement. National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. Clin Chem 1995; 41: 1427-33.

Myers GL, Kimberly MM, Waymack PP, Smith SJ, Cooper GR, Sampson EJ. A reference method laboratory network for cholesterol: a model for standardization and improvement of clinical laboratory measurements. Clin Chem 2000; 46: 1762-72.

Warnick RG, Myers GL, Cooper GR, Rifai N. Impact of the Third Cholesterol Report from the Adult Treatment Panel of the National Cholesterol Education Program on the clinical laboratory. Clin Chem 2002; 48(1): 11-7.

Ridker PM, Hennekens CH, Buring JE. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.

Ridker PM., on behalf of the JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein rationale and design of the JUPITER trial. Circulation 2003; 108: 2292-7.

Kimberly MM, Vesper HW, Caudill SP, Cooper GR, Rifai N, Dati F, et al. Standardization of immunoassays for measurement of high-sensitivity C-reactive protein. Phase I: evaluation of secondary reference materials. Clin Chem 2003; 49: 611-6.

De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003; 10: Suppl 1: 1-78.

Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.

European Society of Cardiology. HeartScore Programme the interactive tool for predicting and managing the risk of heart attack and stroke in Europe. http://www.escardio.org/knowledge/decision_tools/heartscore/

Topol EJ, Lauer MS. The rudimentary phase of personalised medicine: coronary risk scores. Lancet 2003; 362: 1776-7.

Zamaklar M. Konsenzus konferencija o promeni referentnih vrednosti lipida i ciljnim vrednostima lečenja lipidskih poremećaja. Jugoslov Med Biohem 2005; 24: 299-300.

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia

Journal Information


IMPACT FACTOR 2017: 1.378
5-year IMPACT FACTOR: 0.704



CiteScore 2017: 1.05

SCImago Journal Rank (SJR) 2017: 0.307
Source Normalized Impact per Paper (SNIP) 2017: 0.532

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 129 118 3
PDF Downloads 38 35 1